NCI cooperative research and development agreements.
The Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) currently sponsors more than 160 Investigational New Drug applications (INDs), and is involved in approximately 1,600 active protocols. It is also currently involved in more than 50 collaborative agreements with pharmaceutical companies. These agreements consist of cooperative research and development agreements (CRADAs) and clinical trials agreements (CTAs). A CRADA is a detailed contract between the NCI and a pharmaceutical company for the clinical co-development of an investigational agent, and may include preclinical development that stipulates terms for a broader scope of research than that covered by a CTA. The CTEP/Investigational Drug Branch is currently involved in a number of oxaliplatin (Eloxatin) protocols under the CRADA program.
Ivy
S P
SP
Developmental Chemotherapy Section, Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA. Ivyp@ctep.nci.nih.gov
D002985:Clinical Protocols; D003299:Cooperative Behavior; D004345:Drug Industry / Q000458:organization & administration*; D006078:Government Programs / Q000458:organization & administration*; D017408:Guidelines as Topic; D006801:Humans; D008495:Medical Oncology / Q000458:organization & administration*; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000628:therapy*; D012106:Research / Q000458:organization & administration*; D014481:United States